Categories AlphaGraphs, Earnings, Other Industries

Infographic: Altria (MO) Q3 2021 earnings snapshot

Shares of Altria Group, Inc. (NYSE: MO) dropped to an eight-month low recently after the tobacco giant reported weaker than expected earnings and revenues for the third quarter of 2021.

Altria Q3 2021 earnings infographic

Third-quarter earnings, adjusted for special items, moved up to $1.22 per share from $1.19 per share in the comparable period of fiscal 2020. Analysts had forecast a bigger gain. On an unadjusted basis, it was a net loss of $2.72 billion or $1.48 per share, compared to a loss of $952 million or$0.51 per share last year.

Total revenues decreased 4.7% annually to $6.78 billion during the three-month period and came in below analysts’ forecast, reflecting continued weakness in the core tobacco business.

“Our tobacco businesses performed well against difficult year-over-year comparisons and we’re encouraged by the significant retail share growth from on! in the third quarter. We also continued to reward shareholders with a strong and growing dividend and announced today the expansion of our existing $2.0 billion share repurchase program to $3.5 billion,” said Billy Gifford, chief executive officer of Altria.

Read management/analysts’ comments on quarterly results

In the past six months, the company’s stock lost about 7% and mostly underperformed the market. It made modest gains in the pre-market session on Friday, after closing the previous session at $44.75.

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

Biogen (BIIB) stock research summary | Q3 2021

Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of

Teva Pharmaceutical (TEVA) bets on market reopening to regain momentum

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing a slowdown in North American sales. Meanwhile, earnings

Goldman Sachs (GS) stock research summary | Q3 2021

Goldman Sachs (GS) exceeded analysts’ expectations, as investment banking revenue surged nearly 90%. Goldman market research report covers key aspects about the firm including company profile, financial highlights and key

Add Comment
Viewing Highlight